ClinicalTrials.gg
RecruitingNCT06952010Updated Jun 24, 2026

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of XB628 and Zanzalintinib in Solid Tumor, Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Exelixis. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
303
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
208th of 1,863
303 · median 43
Started
2025
with 84 others
Phase 1
709 of 2,054
128 open now
Primary completion
2027-05
later than 222 of 540 live
Registered
1,936th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 208th largest by planned enrollment of the 1,863 interventional ones that give a count, is one of 85 that started in 2025, is one of 709 in phase 1, reaches primary completion later than 222 of the 540 other live ones, and was the 1,936th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.

03

Conditions studied

  • Solid Tumor
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Immune Sensitive Tumor

Browse trials for

Keywords

  • XB628
  • Solid tumor
  • Advanced solid tumor
  • Metastatic solid tumor
  • Immune sensitive tumor
  • PD-L1
  • Zanzalintinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 to 1.
  • Minimum of ≥ 12 weeks.
  • Have a recurrent advanced or solid tumor that is or cytologically confirmed.
  • Adequate organ and marrow function.
  • Not amenable to curative treatment with surgery or radiation.
  • Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting.
  • Acceptable alternative therapy was received, refused, intolerable, or no longer effective.
  • Capable of understanding and complying with the protocol requirements and provide signed according to the protocol and local requirements.

Key Exclusion Criteria

  • Primary brain tumors or known active .
  • Major surgery (eg, gastrointestinal surgery, removal or of brain metastasis) within 4 weeks before the first dose of study treatment.
  • Received radiation therapy within 1 week before the first dose of study treatment or ongoing complications from prior radiation therapy.
  • Received prior therapy targeting NK cells (eg, monalizumab).
  • A woman of has a positive serum pregnancy test within 7 days prior to study treatment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
303 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Phase

    Participants with recurrent advanced or metastatic solid tumors will receive escalating dose levels doses of XB628 as a single agent and in combination with zanzalintinib.

    Biological: XB628 · Drug: Zanzalintinib

  • Experimental
    Dose Expansion

    Participants with recurrent advanced or metastatic solid tumors will receive XB628 as a single agent and in combination with zanzalintinib.

    Biological: XB628 · Drug: Zanzalintinib

Interventions

  • BiologicalXB628

    Intravenous infusion(s)

  • Oral tablet(s)

    Also known as: XL092

06

What researchers measure

Primary outcomes

  1. Dose Escalation Cohort: Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: 21 days

  2. Dose Escalation Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 27 months

  3. Dose Expansion Cohort: Objective Response Rate (ORR)

    Time frame: Up to 27 months

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUC) of XB628

    Time frame: 25 months

  2. Maximum Plasma Concentration (Cmax) of XB628

    Time frame: 25 months

  3. Time to Maximum Concentration (Tmax) of XB628

    Time frame: 25 months

  4. Elimination Half-life (T1/2) of XB628

    Time frame: 25 months

  5. Apparent Clearance (CL/F) of XB628

    Time frame: 25 months

  6. Trough Concentration (Ctrough) of XB628

    Time frame: 25 months

  7. Number of Participants with Antidrug Antibody (ADA) Response to XB628

    Time frame: 25 months

  8. RDE for XB628

    Time frame: 25 months

  9. Dose Expansion Cohort: Duration of Response (DOR)

    Time frame: 27 months

  10. Dose Expansion Cohort: Progression-Free Survival (PFS) of XB628

    Time frame: 27 months

07

Study locations

11 of 11 sites recruiting
  • Exelixis Clinical Site #5
    San Francisco, California 94158, United States
    Recruiting
  • Exelixis Clinical Site #4
    New Haven, Connecticut 06520, United States
    Recruiting
  • Exelixis Clinical Site #8
    Tampa, Florida 33612, United States
    Recruiting
  • Exelixis Clinical Site #10
    Boston, Massachusetts 02114, United States
    Recruiting
  • Exelixis Clinical Site #11
    Boston, Massachusetts 02114, United States
    Recruiting
  • Exelixis Clinical Site #6
    St Louis, Missouri 63108, United States
    Recruiting
  • Exelixis Clinical Site #7
    New York, New York 10029, United States
    Recruiting
  • Exelixis Clinical Site #1
    Hickory, North Carolina 28602, United States
    Recruiting
  • Exelixis Clinical Site #3
    Nashville, Tennessee 37203, United States
    Recruiting
  • Exelixis Clinical Site #9
    Houston, Texas 77030, United States
    Recruiting
  • Exelixis Clinical Site #2
    San Antonio, Texas 78229, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
Apr 30, 2025
StartActual
May 1, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952010
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
May 1, 2025
Primary completion
May 31, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
650-837-7400
Medical Director
study director · Exelixis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion